Lung Cancer | Specialty

Combined Immunotherapy and Chemotherapy for NSCLC

June 23rd 2017

Checkpoint Inhibitors for Relapsed or Refractory NSCLC

June 23rd 2017

Update on PD-L1 Testing for NSCLC

June 23rd 2017

Upfront Immunotherapy for PD-L1+ NSCLC

June 23rd 2017

FDA Approves Dabrafenib/Trametinib Combo for BRAF+ NSCLC

June 23rd 2017

The FDA approved the combination of dabrafenib and trametinib for patients with BRAF V600–positive advanced or metastatic non–small cell lung cancer.

Dr. Verschraegen on Combining Immunotherapy Agents in Lung Cancer

June 22nd 2017

Claire Verschraegen, MD, professor of medical oncology, University of Vermont Cancer Center, discussing combining avelumab (Bavencio) with other immunotherapy agents for patients with lung cancer.

Dr. Gandhi on Pembrolizumab/Chemo Findings in NSCLC and FDA Approval

June 21st 2017

Leena Gandhi, MD, PhD, associate professor, Department of Medicine, director, Thoracic Medical Oncology Program, discusses the findings of cohort G of the KEYNOTE-021 trial that explored the combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed for patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

Dr. Hellmann on Nivolumab in Combination with Ipilimumab for Small Cell Lung Cancer

June 20th 2017

Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

Considerations for Sequencing in ALK+ NSCLC

June 16th 2017

FDA Approval: Frontline Ceritinib for ALK+ NSCLC

June 16th 2017

Next-Generation ALK-Targeted Agents in NSCLC

June 16th 2017

Development of ALK-Targeted Therapy for NSCLC

June 16th 2017

Osimertinib Improves Response in T790M+ NSCLC With CNS Metastases

June 9th 2017

Patients with T790M-positive non–small cell lung cancer had superior outcomes when treated with osimertinib (Tagrisso) for central nervous system metastases, according to phase III results presented at the 2017 ASCO Annual Meeting.

Combo Regimens, Optimal Sequencing Key to Advances in EGFR+ and ALK+ NSCLC

June 8th 2017

Christine M. Lovly, MD, PhD, discusses the changing treatment landscape for patients with EGFR-mutant and ALK-positive NSCLC.

Sacituzumab Govitecan Induces Durable Responses in NSCLC

June 7th 2017

Results from a single-arm, multicenter trial showed that the antibody-drug conjugate sacituzumab govitecan (IMMU-132) was well-tolerated and produced a median duration of response of 6.0 months in previously treated patients with metastatic non–small cell lung cancer.

Dr. Zulueta on the Application of the LuCED Test for Lung Cancer

June 6th 2017

Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.

Dr. Garassino Discusses Promising Findings With Osimertinib for Patients With NSCLC and Brain Mets

June 6th 2017

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses a subset analysis of the AURA3 trial, which demonstrated significant clinical activity with osimertinib (Tagrisso) for patients with EGFR T790M-mutation positive non–small cell lung cancer (NSCLC) who also harbor brain metastases.

Dr. West on Emerging Changes in the Field of EGFR-Mutant NSCLC

June 6th 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses some potential emerging changes coming to the field of EGFR-mutant non–small cell lung cancer (NSCLC), including next-generation EGFR inhibitors such as osimertinib (Tagrisso) that is now being explored in the FLAURA trial as a frontline treatment for these patients.

Dr. Shaw on the Phase III Results of the ALEX Trial in NSCLC

June 6th 2017

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses the phase III results of the international ALEX trial, which compared the alectinib (Alecensa) with crizotinib (Xalkori) in the frontline setting for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

The Design Behind the Development of a Novel-Risk Prediction Model in Lung Cancer Screening

June 6th 2017

Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the design of a novel risk-prediction algorithm in the context of screening patients for lung cancer.